1.229

8.34% -0.111

Taysha Gene Therapies Inc (TSHA)

Overview News Price History Option Chain Financials Discussions Forecast

Taysha Gene Therapies Inc stock is traded at $1.229, with a volume of 9.76M. It is down -8.34% in the last 24 hours and down -38.89% over the past month. Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Previous Close:

$1.34

Open:

$1.34

24h Volume:

9.76M

Relative Volume:

5.46

Market Cap:

$250.01M

Revenue:

$12.87M

Net Income/Loss:

$-114.34M

P/E Ratio:

-0.5367

EPS:

-2.29

Net Cash Flow:

$-79.23M

1W Performance:

-34.66%

1M Performance:

-38.89%

6M Performance:

-52.21%

1Y Performance:

-50.47%

1-Day Range:

$1.19

$1.355

1-Week Range:

$1.19

$1.93

52-Week Range:

$1.19

$4.32

Taysha Gene Therapies Inc Stock (TSHA) Company Profile

Name

Taysha Gene Therapies Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(214) 612-0000

Address

3000 PEGASUS PARK DRIVE, DALLAS

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

TSHA's Discussions on Twitter

Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-01-23	Downgrade	Jefferies	Buy → Hold
Jan-27-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-22	Downgrade	Goldman	Buy → Neutral
Mar-09-22	Initiated	Robert W. Baird	Outperform
Mar-01-22	Initiated	Wells Fargo	Overweight
Feb-18-22	Initiated	SMBC Nikko	Outperform
Dec-16-21	Initiated	Guggenheim	Buy
Jul-16-21	Initiated	Needham	Buy
Jun-24-21	Initiated	Truist	Buy
Jun-15-21	Initiated	BTIG Research	Buy
Jun-09-21	Initiated	Wedbush	Outperform
Jun-08-21	Initiated	JMP Securities	Mkt Outperform
May-19-21	Initiated	Cantor Fitzgerald	Overweight
May-11-21	Resumed	Jefferies	Buy
Feb-24-21	Initiated	William Blair	Outperform
Jan-05-21	Initiated	Oppenheimer	Outperform
Oct-19-20	Initiated	Chardan Capital Markets	Buy
Oct-19-20	Initiated	Goldman	Buy
Oct-19-20	Initiated	Jefferies	Buy
Oct-19-20	Initiated	Morgan Stanley	Overweight

View All

Taysha Gene Therapies Inc Stock (TSHA) Latest News

Nov 01, 2024

TSHATaysha Gene Therapies, Inc. Latest Stock News & Market Updates - StockTitan

Nov 01, 2024

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Nov 01, 2024

Oct 29, 2024

ABEOAbeona Therapeutics Inc. Latest Stock News & Market Updates - StockTitan

Oct 29, 2024

Oct 26, 2024

SG Americas Securities LLC Purchases Shares of 63,984 Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World

Oct 26, 2024

Oct 24, 2024

Taysha Gene Therapies' SWOT analysis: promising gene therapy stock faces key catalysts - Investing.com

Oct 24, 2024

Oct 22, 2024

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress - The Manila Times

Oct 22, 2024

Taysha Gene Therapies to Present Biodistribution Data from - GlobeNewswire

Oct 22, 2024

Oct 16, 2024

Is Taysha Gene Therapies, Inc. (TSHA) the Most Promising Biotech Stock According to Hedge Funds? - Insider Monkey

Oct 16, 2024

Oct 15, 2024

Trading Day Review: Taysha Gene Therapies Inc (TSHA) Loses Momentum, Closing at 1.99 - The Dwinnex

Oct 15, 2024

Can you now get a good deal on Taysha Gene Therapies Inc’s shares? - US Post News

Oct 15, 2024

Benitec Biopharma’s Oculopharyngeal Muscular Dystrophy Gene Therapy Produces Clinical Improvements in Swallowing in Phase 1b/2a Trial - CGTLive™

Oct 15, 2024